Sarcosine

Catalog No.S4702 Synonyms: N-methylglycine, Sarcosinic acid, Methylaminoacetic acid, Methylglycine

For research use only.

Sarcosine (N-methylglycine, Sarcosinic acid, Methylaminoacetic acid, Methylglycine) is a competitive inhibitor of the type I glycine transporter (GlyT1) and an N-methyl-D-aspartate receptor (NMDAR) co-agonist.

Sarcosine Chemical Structure

CAS No. 107-97-1

Purity & Quality Control

Choose Selective NMDAR Inhibitors

Biological Activity

Description Sarcosine (N-methylglycine, Sarcosinic acid, Methylaminoacetic acid, Methylglycine) is a competitive inhibitor of the type I glycine transporter (GlyT1) and an N-methyl-D-aspartate receptor (NMDAR) co-agonist.
Targets
GlyT1 [1] N-methyl-D-aspartate receptor [1] GlyR [1]
In vitro

Sarcosine is a GlyR agonist in addition to being a GlyT1 inhibitor and NMDAR co-agonist, but it is less potent than glycine as a GlyR agonist and is not a full agonist[1]. The viability of the sarcosine-treated cells is significantly reduced[4].

In vivo Sarcosine has weak anticonvulsant properties[2]. It ameliorates (prepulse inhibition)PPI deficits in mGluR5 knockout mice[3].

Protocol (from reference)

Cell Research:[4]
  • Cell lines: PC-3 prostate cancer cell line
  • Concentrations: 10, 150, 250, 500, 1,000 and 1,500 μM
  • Incubation Time: 0, 6, 12, 24 and 72 h
  • Method: Immediately after the cells grow to 50-60% confluence, the cultivation medium is replaced by fresh medium to synchronise cell growth. Cells are cultivated for 24 h under these conditions. Subsequently, the culture medium is supplemented with sarcosine (N-methylglycine) diluted to a final concentration 10, 150, 250, 500, 1,000 and 1,500 μM. Treatment is carried out for 0, 6, 12, 24 and 72 h, and samples are collected at these strictly defined time points.
Animal Research:[2]
  • Animal Models: Male Albino Swiss mice
  • Dosages: 100,200,400 and 800 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 89.09
Formula

C3H7NO2

CAS No. 107-97-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CNCC(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04949607 Not yet recruiting Dietary Supplement: Inulin fructooligosaccharide Brain Injury Chronic|Brain Injuries Traumatic Centre for Neuro Skills|University of Texas July 1 2021 Not Applicable
NCT02404337 Completed Drug: Betaine Homocystinuria Assistance Publique - Hôpitaux de Paris July 2015 Phase 2
NCT02462447 Completed Drug: 11C-sarcosine|Drug: 11C-choline Prostate Cancer University of Michigan|National Institutes of Health (NIH)|National Cancer Institute (NCI) June 2015 --
NCT01503359 Completed Dietary Supplement: Sarcosine Schizophrenia Medical University of Lodz January 2012 Phase 2
NCT00276263 Withdrawn Drug: Sarcosine (N-methylglycine) Schizophrenias|Psychoses|Psychotic Disorders|Schizophrenic Disorders Herzog Hospital August 2006 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Sarcosine | Sarcosine supplier | purchase Sarcosine | Sarcosine cost | Sarcosine manufacturer | order Sarcosine | Sarcosine distributor